Literature DB >> 1888156

Intravesical Bacillus Calmette-Guérin treatment for superficial bladder cancer: results after 15 years of experience.

A P van der Meijden1, P A Steerenberg, W H de Jong, F M Debruyne.   

Abstract

Superficial bladder cancer has a high recurrence rate and considerable progression rate. The treatment currently consists of resection and adjuvant intravesical chemotherapy or immunotherapy. Intravesical instillation of Bacillus Calmette-Guérin (B.C.G.) is considered to be one of the most successful immunotherapies in man. Durable response rates of 60-70% are achieved. Toxicity is more pronounced in comparison with intravesical chemotherapy. In this article we describe the experience with B.C.G. during the last 15 years. No consensus has been reached yet about the ideal treatment scheme, appropriate strain and optimal dosage. The mechanisms of action are complicated and still not completely understood.

Entities:  

Mesh:

Year:  1991        PMID: 1888156

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

Authors:  A M Jackson; A B Alexandroff; R W Kelly; A Skibinska; K Esuvaranathan; S Prescott; G D Chisholm; K James
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

2.  Bacillus calmette-guerin infection in NADPH oxidase deficiency: defective mycobacterial sequestration and granuloma formation.

Authors:  Christine Deffert; Michela G Schäppi; Jean-Claude Pache; Julien Cachat; Dominique Vesin; Ruth Bisig; Xiaojuan Ma Mulone; Tiina Kelkka; Rikard Holmdahl; Irene Garcia; Maria L Olleros; Karl-Heinz Krause
Journal:  PLoS Pathog       Date:  2014-09-04       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.